An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.